TOKYO — Sound Wave Innovation has closed a 2.65 billion yen funding round. The sum equals about $17 million. The Japanese startup will use the cash to finish a pivotal clinical trial of its low-intensity pulsed ultrasound device aimed at patients with early-stage Alzheimer’s disease.
The round, completed this week, drew participation from iGlobe Partners, Fiducia and Sumitomo Heavy Industries. It arrives at a moment when conventional drug therapies for Alzheimer’s face questions over cost, side effects and variable results. Sound Wave’s approach sidesteps pills and infusions. Patients wear a headset that delivers gentle ultrasound pulses across the brain. No surgery. No anesthesia. Sessions last until the treatment ends, with intensity levels comparable to standard diagnostic scans.
Dr. Hiroaki Shimokawa founded the company. The emeritus professor at Tohoku University built on years of research showing that these pulses can stimulate vascular endothelial cells. The process up-regulates enzymes and growth factors. Blood flow improves. Microcirculation gets a boost. In mouse models of Alzheimer’s, cognitive decline slowed. Early human data pointed the same direction.
From Lab Insight to Regulatory Push
The technology earned a breakthrough medical device designation from Japan’s Ministry of Health, Labour and Welfare in 2022. It was the first such nod. An exploratory trial wrapped up that same year. Safety looked solid. Hints of efficacy appeared strong enough to greenlight a larger study. The pivotal LIPUS-AD trial launched in October 2023. It enrolled 220 patients with early Alzheimer’s confirmed by amyloid PET scans. The design is randomized, double-blind and placebo-controlled. Target enrollment was hit by late 2024. Completion now stands scheduled for the end of 2026. Approval could follow in 2027.
A baseline paper for the study appeared online in the Journal of Alzheimer’s Disease Reports in late 2025. The work underscores the mechanism. Ultrasound doesn’t blast plaques directly. It prompts the brain’s own systems to function better. Think enhanced clearance and reduced inflammation through better vascular health. But data from the full trial will decide whether those signals translate into measurable cognitive gains for patients.
Sumitomo Heavy Industries brings more than money. The industrial giant signed a strategic partnership with Sound Wave in September 2025. SHI will handle manufacturing and distribution of the LIPUS-Brain device once approved. Sound Wave will license its intellectual property and continue to drive the trial. The alliance fits SHI’s Medium-Term Management Plan 2026. Advanced medical devices rank as one of four focus areas alongside robotics, semiconductors and energy. The company sees the partnership as a way to combine its production expertise with Sound Wave’s deep-tech origins.
“This investment and business partnership with SWI involve our participation in minimally invasive treatment of dementia using the Low-Intensity Pulsed Ultrasound,” SHI stated in its announcement. The release highlights the societal burden of Alzheimer’s on patients, families and caregivers. It positions the device as a new option that demands minimal physical stress. The headset sits comfortably. Treatment happens in ordinary medical settings, large or small.
Investors appear to share the optimism. Singapore-based iGlobe Partners led the latest round. Fiducia joined too. The participation of Sumitomo Heavy Industries signals industrial conviction. This isn’t pure venture risk. It’s a bet on scalable production and market entry in Japan first, with potential expansion later.
But challenges remain. Alzheimer’s trials have a long history of disappointment. Many therapies that looked promising in smaller studies faltered at scale. Sound Wave’s whole-brain approach differs from focused ultrasound systems used elsewhere. Those often target specific regions to open the blood-brain barrier temporarily, sometimes to deliver drugs. Here the pulses act directly on vascular function across the entire organ. The company has built patents around the non-converging energy delivery method. Yet peer-reviewed outcomes from the pivotal phase will carry the real weight.
Interest in ultrasound for brain disorders has grown. Researchers at other institutions have tested similar concepts for dementia and beyond. Sound Wave’s work stands out for its non-invasive simplicity and the volume of Japanese clinical data already gathered. A 2023 BioWorld article noted the company’s efforts to secure intellectual property not just for Alzheimer’s but also for heart disease applications. The platform could stretch across multiple conditions tied to microcirculatory problems.
The funding news broke amid a broader pickup in Japanese deep-tech investment. Startups in AI, fusion and advanced materials have drawn large checks lately. Sound Wave’s round, while smaller, targets one of society’s most pressing health issues. Dementia cases continue to climb as populations age. Effective, accessible treatments could ease enormous pressure on healthcare systems.
Completion of the trial by the end of this year. That’s the immediate milestone. Positive results would open the door to regulatory submission. Commercial launch might follow quickly in Japan given the breakthrough designation. Wider adoption would depend on reimbursement talks and physician acceptance. The device must prove not only that it works but that it fits into real-world practice without adding complexity.
Shimokawa has long championed the potential. His dual role as founder and chief medical officer ties academic roots to commercial execution. The company relocated its head office in April 2026. It won awards and government grants in recent months. Those steps suggest operational momentum as the trial winds down.
Analysts watching the neurodegenerative space say non-drug approaches could complement existing therapies. Anti-amyloid antibodies have reached the market but carry high price tags and monitoring requirements. A safe, repeatable ultrasound treatment might serve patients who don’t qualify for biologics or who seek alternatives. Much hinges on the numbers that emerge from the 220-person study.
For now the focus stays narrow. Finish enrollment analysis. Lock in the data. Prepare the submission. The $17 million infusion buys time and resources to do exactly that. If the results hold, Sound Wave could shift from startup to established player in Japan’s medical device sector. Sumitomo’s manufacturing muscle stands ready. The headset technology, once obscure, may soon reach clinics nationwide.
And the implications stretch further. Success here would validate years of basic research on vascular stimulation. It could spur similar efforts for other intractable conditions. But first comes the readout. Investors, patients and physicians all wait for those figures. The sound waves have been sent. The echo will arrive soon.
WebProNews is an iEntry Publication